Replies to post #37084 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

It appears CTMX had a $700 million valuation before this deal, now the valuation will be over $900 million.

Looking at it from a slightly different perspective, CTMX's deal with Amgen is very similar to our deal with Amgen but our terms were actually slightly better. The impact of our Amgen deal was short-lived on ADXS' valuation due to Dan's post deal dilution and implicit helping the shorts. By contrast, the afterhours appreciation of CTMX following their Amgen deal is an increase of more than $200 million to its market cap, so this single deal CTMX struck with Amgen that is nearly identical to our deal with Amgen is adding incremental value to CTMX's market value in an amount MORE THAN ADXS' ENTIRE COMPANY MARKET VALUE.

Lesson learned over the last four years as an ADXS investor...management matters and poor management can destroy shareholder value significantly even if clinical trials are progressing positively. Hoping for better days ahead with Lombardo.

[mypekeispooped]

From what I can see, they only have two P1 trials at the moment. We should be far ahead of their PPS.